Submitted by web@researchtop... on Wed, 05/15/2019 - 14:49
Interview with Andreas Rimner, MD
Interview with Corey J Langer, MD
Track 1:
Case: A woman in her mid-60s, a never smoker, with locally advanced, unresectable adenocarcinoma of the lung and an EGFR exon 18 tumor mutation receives CRT followed by consolidation durvalumab
Track 2:
Clinical significance and prognostic relevance of microsatellite instability testing in the management of lung cancer
Track 3:
Risk of recurrence after concurrent CRT for patients with Stage III NSCLC
Track 4:
Improvement in progression-free and overall survival with the addition of consolidation durvalumab after CRT for patients with Stage III NSCLC on the PACIFIC trial
Track 5:
Role of immune checkpoint inhibition in the treatment of locally advanced NSCLC with an EGFR tumor mutation
Track 6:
Perspective on the use of EGFR tyrosine kinase inhibitors in the adjuvant or neoadjuvant setting for patients with locally advanced NSCLC and EGFR tumor mutations
Track 7:
Initial diagnostic workup and disease management for patients with locally advanced NSCLC
Track 8:
RTOG-1308: An ongoing Phase III trial of photon versus proton CRT for patients with inoperable Stage II to Stage IIIB NSCLC
Track 9:
Role of proton beam RT in the treatment of locally advanced NSCLC
Track 10:
Rationale for the combination of RT and immune checkpoint inhibitors
Track 11:
Risk of pneumonitis with CRT
Track 12:
Design and results of the Phase III PACIFIC trial of durvalumab after CRT for unresectable Stage III NSCLC
Track 13:
Monitoring and management of the toxicities associated with immune checkpoint inhibitors
Track 14:
Use of durvalumab for patients with preexisting autoimmune disease and for transplant recipients
Track 15:
Results from the Phase II Hoosier Cancer Research Network LUN14-179 trial of consolidation pembrolizumab after CRT for unresectable Stage III NSCLC
Track 16:
Ongoing investigation of anti-PD-1/PD-L1 immune checkpoint inhibitors for locally advanced disease
Track 17:
Case: A man in his mid-80s, a former heavy smoker with multiple comorbidities, is diagnosed with locally advanced squamous cell carcinoma of the lung with a high PD-L1 TPS (tumor proportion score)
Track 18:
Use of liquid biopsies to detect targetable tumor mutations in patients with lung cancer
Track 19:
Case: A man in his mid-50s, a former smoker, is diagnosed with Stage IIIA mixed adenosquamous carcinoma of the lung with TTF-1 and p40 tumor mutations
Track 20:
Perspective on the use of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for patients with NSCLC
Track 21:
Case: A man in his early 70s, a current smoker, with adenosquamous carcinoma of the lung and a KRAS mutation receives SBRT
Track 22:
Optimal approach to RT for patients with locally advanced NSCLC
FACULTY
Andreas Rimner, MD
Associate Attending
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
EDITOR
Neil Love, MD
Research To Practice
Miami, Florida